Glenmark Therapeutics Launches Olopatadine Ophthalmic Solution 0.1% OTC In The U.S. Market

Glenmark Therapeutics, USA, a subsidiary of Glenmark Pharmaceuticals, launched its Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1 per cent (OTC). 

The company in a press statement on Monday said that the product is positioned as an over-the-counter alternative comparable to the active ingredient in Pataday Twice Daily Relief.

The introduction of this new ophthalmic solution comes in response to a growing demand for additional suppliers in the OTC eye care market. According to Nielsen syndicated data for the 52 weeks ending July 13, 2024, Pataday Twice Daily Relief (OTC) garnered approximately USD 26.4 million in annual sales.

Fabio Moreno, Head of OTC Sales & Marketing at Glenmark Pharmaceuticals Inc., expressed enthusiasm about the launch, stating, "We are excited to announce the launch of Olopatadine Ophthalmic Solution USP, 0.1 per cent, addressing the growing demand for a new supplier in this category. This addition highlights our commitment to meeting market needs and providing high-quality over-the-counter solutions for our customers."

This product launch underscores Glenmark's ongoing efforts to expand its OTC portfolio and meet the diverse needs of consumers.